PAM
SABSW icon

Panagora Asset Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Panagora Asset Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,501
Closed -$5K – 2933
2021
Q1 		$5K Buy
+7,501
New +$7.79K ﹤0.01% 2589

Other funds holding SABSW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.62% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Panagora Asset Management's SABSW Position: Q2 2021 in Review

Panagora Asset Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q2 2021, closing a stake of 7,501 shares — an estimated $5K sold.

Panagora Asset Management first reported a position in SABSW in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 24 funds tracked by Wall St. Rank hold SABSW as of Q2 2021.

  • Panagora Asset Management reported no remaining SAB Biotherapeutics Warrant position as of Q2 2021 after selling out during the quarter.
  • Panagora Asset Management sold 7,501 SAB Biotherapeutics Warrant shares in Q2 2021, an estimated $5K.
  • Panagora Asset Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 1 quarter.
  • Panagora Asset Management's SAB Biotherapeutics Warrant position peaked at $5K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2021.

Based on Panagora Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.